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Migraine and possible etiologic 
heterogeneity for hormone-
receptor-negative breast cancer
Min Shi1, Lisa A. DeRoo2,3, Dale P. Sandler3 & Clarice R. Weinberg1
Migraine headache is often timed with the menstrual cycle. Some studies have reported reduced 
risk of breast cancer in migraineurs but most of those did not distinguish menstrually-related from 
non-menstrually-related migraine. To examine the possible associations between breast cancer 
and migraine overall and between cancer subcategories and the two migraine subtypes, we used 
a cohort study of 50,884 women whose sister had breast cancer and a sister-matched case-control 
study including 1,418 young-onset (<50 years) breast cancer cases. We analyzed the two studies 
individually and also in tandem via a hybrid Cox model, examining subcategories of breast cancer in 
relation to menstrually-related and non-menstrually-related migraine. History of migraine was not 
associated with breast cancer overall. Migraine showed an inverse association with ductal carcinoma 
in situ (HR = 0.77; 95% CI (0.62,0.96)). Also, women with non-menstrually-related migraine had 
increased risk (HR = 1.30, 95% CI (0.93,1.81)) while women with menstrually-related migraine had 
decreased risk (HR = 0.63, 95% CI (0.42,0.96)) of hormone-receptor-negative (ER−/PR−) cancer, with 
a significant contrast in estimated effects (P = 0.005). While replication of these subset-based findings 
will be needed, effect specificity could suggest that while migraine has little overall association with 
breast cancer, menstrual migraine may be associated with reduced risk of ER−/PR− breast cancer.
Migraine headache is a common and chronic disorder that occurs more often in women than men1. 
Slightly more common in girls than in boys, after puberty the prevalence of migraine increases in 
females, rising to a peak in the early 40 s1. The rate of new diagnoses declines after menopause2, after 
which prevalence also declines3.
Migraine can be sensitive to hormones. Approximately 50% of women with migraine report that 
attacks tend to be synchronized with their menstrual cycle4. The typical pattern is that headache begins 
within a day or two before menses onset, during the fall of estrogen at the end of the cycle. Randomized 
placebo-controlled clinical trials have suggested some prophylactic therapeutic benefit from estrogen 
therapy for menstrual migraine, consistent with hormone sensitivity5,6.
Breast cancer is also related to hormones: higher rates are seen in women with early age at menarche, 
late age at first birth, and late age at menopause7,8. The use of peri- and postmenopausal hormone 
replacement therapy can increase the risk of breast cancer9,10. A positive association between endogenous 
levels of blood estrogen and androgen and postmenopausal breast cancer has been reported in several 
studies11–13, and a recent nested case-control study within the Nurses’ Health Study showed that a single 
blood-based sex hormone measurement predicted breast cancer risk even 16–20 years later14. Tumors 
are categorized according to whether they express hormone receptors and consequently are hormone 
sensitive or not, a difference with implications both for treatment and prognosis15.
An association between migraine and breast cancer risk has been hypothesized. Several studies 
reported an inverse association, with 10–30% reduction in risk in women with a migraine history16–18. 
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This inverse association was not replicated by a recent analysis based on the Women’s Health Study19. 
None of the studies distinguished menstrually-related from other migraine. We used data from the Sister 
Study cohort of 50,884 women whose sister had breast cancer, and the Two Sister Study, a sister-matched 
case-control study of 1,418 breast cancer cases diagnosed before age 50. We analyzed the two studies 
separately and also in combination. We examined subcategories of breast cancer (invasive breast cancer 
versus ductal carcinoma in situ (DCIS), estrogen-receptor/progesterone-receptor (ER/PR) positive versus 
negative, and hormone receptor negative and HER2 negative (triple negative) versus others) in relation 
to menstrually-related and other migraine. Our objective was to determine whether migraine per se 
was associated with the risk of breast cancer and whether that association differed by tumor subtype or 
was modified by whether or not the migraine was menstrually related. We took advantage of two large 
studies that had used very different designs: one (Sister Study) was prospective, population-based and 
required a first-degree family history, while the other (Two Sister Study) was retrospective, family-based 
and included only about 20% with a first-degree family history. Because the two could be analyzed in a 
way that ensured statistical independence of findings, we were able to assess reproducibility of findings.
Methods
The two studies. The Sister Study recruited 50,884 women in the United States and Puerto Rico 
(http://sisterstudy.niehs.nih.gov/English/about.htm), who were age 35 to 74 at enrollment in 2004–2009 
and had a sister with breast cancer, but had never been diagnosed with breast cancer themselves20. 
Participants provided information on demographic and lifestyle characteristics, family history, medical 
conditions, reproductive history, and occupational and environmental exposures. Incident breast cancer 
cases were identified over a mean follow-up of 5.34 years, based on annual health updates and biennial/
triennial questionnaires and confirmed through additional participant contact and retrieval of medical 
records.
The Two Sister Study (http://www.sisterstudy.niehs.nih.gov/English/2sis.htm) is a family-based retro-
spective case-control study ancillary to the Sister Study. With the help of already-identified Sister Study 
participants, we enrolled case sisters who had been diagnosed recently (within 4 years) and under age 
50. Enrollment took place from September 2008 to December 2010. Both the Sister Study and the Two 
Sister Study secured informed consent and were carried out with human subjects approval and oversight 
from the NIEHS Institutional Review Board and the Copernicus Group Institutional Review Board. Both 
studies were carried out in accordance with the approved guidelines.
Participants all completed the same risk factor questionnaires. In addition, cases provided details on 
their breast cancer diagnosis, tumor characteristics, and treatment, and they authorized access to medical 
records. Tumor subtypes (ER, PR, and human epidermal growth factor receptor 2 (HER2)) were ascer-
tained from medical records (80%–89%) when available, or from self-report (11%–20%). Agreement 
between these two sources was excellent21. We also carried out exploratory analyses based on subcatego-
rizing invasive cancer by histologic type as lobular or ductal.
The baseline questionnaire included the question: “Has a doctor or other health professional ever told 
you that you had migraine headaches?” Those who responded “Yes” were then asked the age at which 
that diagnosis had been made. Responses to the additional question “Have you ever noticed a pattern 
where your migraine headaches got worse at certain times of your menstrual cycles?” were used to 
classify migraine as menstrual versus nonmenstrual. Women with both types were categorized as having 
menstrual migraines. We also collected data on use of migraine medications, for sensitivity analyses. 
Data were not collected on family history of migraine.
Statistical Analysis. Data from the prospective Sister Study cohort was modeled using Cox propor-
tional hazards regression, with age as the primary time scale. Follow-up began at enrollment (or to avoid 
overlap, for Two Sister controls follow-up began at the age at which their proband sister was diagnosed, if 
that was later) and ended at breast cancer diagnosis or (for women remaining without breast cancer) age 
at most recent follow-up. For assessing associations with specific subcategories of breast cancer, diagno-
ses of other types or of unknown subcategory were treated as censoring events that truncated time at risk.
Cox proportional hazards regression is equivalent to conditional logistic regression with fine stratifi-
cation on ages at events, and data from the Two Sister Study were also analyzed with conditional logistic 
regression, but with additional stratification on sibship. For many families the matched control sister 
was older than their case sister, because eligible case sisters had to have been under age 50 at diagnosis 
by design. We used “index age” to ensure comparable opportunity for time-dependent exposures in 
within-sibship comparisons, as previously described21. Briefly, index age was defined for each set of 
sisters as the smallest of the reported age of the case sister at diagnosis and the age(s) of her control 
sister(s) at completion of enrollment. For example, if the case sister was diagnosed at 48 and her control 
sister enrolled at age 50, the index would be 48 for the sister pair. The exposure experienced by the con-
trol sister between 48 and 50 was not considered to be relevant. For most sibships (N = 893) the index 
age was the same as the age at diagnosis and for others it was somewhat younger. For Two Sister Study 
analyses women were categorized as having migraine only if their stated age at migraine diagnosis was 
earlier than their sibship’s index age. (Migraine tends to be diagnosed early in life and few (N = 54) had 
been diagnosed with migraine after the index age, but to ensure comparable opportunity to have had a 
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migraine diagnosis, such women were not considered to have migraine in our analyses.) The use of index 
age in this way accomplishes age adjustment in the analysis of the Two Sister Study.
We also carried out completely separate analyses and used meta-analyses to combine the results of 
the separately-analyzed two studies (with inverse variance weighting) to confirm that the point estimates 
based on combined-analysis and meta-analysis were similar.
Despite the fact that some of those followed in the Sister Study also served as controls for the Two 
Sister Study, the two studies provide statistically independent inference. This independence arises from 
the fact that the overall likelihood is the product of the two likelihoods. The Cox model (as with all life 
table methods) treats outcomes at different event times as statistically independent (under a Markov 
assumption), and controls are used over and over again in the same analysis, until they become cases. 
One consequence is that the overall likelihood is the product of many separate likelihoods, one for each 
event time. The control sister for the Two Sister Study was eligible to be a control because she was free 
of cancer at the age when her sister was diagnosed. Her own subsequent experience with breast cancer 
risk in the Sister Study follow-up was analyzed prospectively. To ensure that the two studies contributed 
independently to the analysis, we started the clock for the Sister Study likelihood either at the partici-
pant’s age at completion of enrollment or, if she was also serving as a control for Two Sister, at the age 
when her proband sister was diagnosed, whichever was later. Thus the two designs are separable and 
provide non-overlapping, statistically independent inference.
Migraine history was coded as either a binary variable or a three-level variable (no migraine, 
nonmenstrually-related, and menstrually-related migraine). A small number of women who did not spec-
ify menstrually-related or not (1.2% of total migraine reporters) were treated as nonmenstrually-related, 
presuming that a relationship with menses would have been noticed. We separately evaluated association 
with invasive breast cancer and ductal carcinoma in situ (DCIS). The invasive cancer subgroup analyses 
were further divided into tumor-based estrogen receptor/progesterone receptor (ER/PR) status subtypes. 
Cases missing ER/PR status were treated as censored at diagnosis for the Sister Study and were excluded 
for Two Sister. We adjusted for the following potential confounders identified by consideration of directed 
acyclic graphs (DAG)22: race, age at menarche, nulliparity, body mass index (BMI) age at first term birth 
for parous women and menopausal status. We assessed heterogeneity between menstrually-related and 
nonmenstrually-related migraine by using likelihood ratio tests of the null hypothesis that the migraine 
coefficients are the same. We also explored effect modification by age at risk, menopause status and BMI 
as recalled for when they were in their 30 s via likelihood ratio testing. We also conducted case-only 
logistic analysis23,24, which included all cases, to examine etiologic heterogeneity across cancer subcatego-
ries, adjusting for race, age at diagnosis, age at menarche, study, and age at first birth. As a spline model 
did not improve the fit, age at diagnosis was included linearly in case-only analyses.
All analyses were done using the SAS software, PHREG and LOGISTIC procedures, version 9.3 (SAS 
Institute, Inc., Cary, NC). All statistical tests were two-sided.
Results
Similar percentages of women in the Sister (20.7%) and Two Sister (18.5%) studies reported migraine 
history and among them similar percentages, 44.5% (Sister) and 45.5% (Two Sister), reported their 
migraine tended to be timed to the menstrual cycle, referred to as menstrually-related migraine. Table 1 
shows characteristics of participants in the two studies stratified by migraine status. The mean ages of 
women without migraine and those with nonmenstrually-related migraine in the Sister Study were sim-
ilar (56 years) while those reporting menstrually-related migraine were slightly younger (mean age = 54 
years). The mean index age of the Two Sister Study participants was 44 and did not depend on migraine 
status. The mean age of control sisters was 47.3 (standard deviation [SD] = 6.3 years) at enrollment and 
the mean age of case sisters was 47.3 (SD = 4.1 years) at enrollment, and 44.7 (SD = 4 years) at diagnosis. 
Overall, characteristics were similar for participants across the two migraine categories in both stud-
ies, except that women with menstrual migraine were more often pre-menopausal at interview. During 
a mean follow up of 5.3 years (270,866 person-years), 2,118 newly incident breast cancer cases were 
reported in the Sister Study, which included 1,534 invasive and 488 DCIS cases. The Two Sister Study 
retrospectively included 1,200 invasive and 203 DCIS cases.
As shown in Table 2, neither category of migraine was significantly associated with breast cancer over-
all [combined-analysis adjusted HR = 1.03 (0.90, 1.18) for nonmenstrually-related migraine, HR = 0.91 
(0.77, 1.07) for menstrually-related migraine] or with invasive breast cancer [combined-analysis adjusted 
HR = 1.07 (0.93, 1.22) for nonmenstrually-related migraine, HR = 0.94 (0.80, 1.10) for menstrually-related 
migraine]. An inverse association between undifferentiated migraine and DCIS was observed in the 
Sister Study (adjusted HR = 0.73 (0.57, 0.94) for any migraine) and in the combined analysis, but was 
not seen in the Two Sister Study (adjusted OR = 1.04 (0.61, 1.79). The association with DCIS in the Sister 
Study was similar for nonmenstrually-related (adjusted HR = 0.73 (0.53, 1.01) versus menstrually-related 
(adjusted HR = 0.73 (0.51, 1.05)) migraine.
Migraine was not associated with ER+ /PR+ invasive cancer in either study (combined-analysis 
adjusted HR = 1.03 (0.86, 1.23) for nonmenstrually-related migraine, HR = 1.04 (0.86, 1.27) for 
menstrually-related migraine) (Table  2). For invasive ER− /PR− cancer, there was again no over-
all association between migraine and risk (combined-analysis adjusted HR = 0.96 (0.73, 1.26)). 
The meta-analysis results were similar to the combine-analysis results (adjusted HR = 0.95 (0.72, 
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Characteristic




















Mean age at baseline
55.9 55.8 53.9 47.9 46.9 46.9
Mean index age
— — — 43.5 43.6 43.5
Race
 Non-Hispanic white 33536 (84) 4843 (83) 3959 (85) 1206 (89) 150 (89) 126 (90)
 Black 3759 (9) 499 (9) 318 (7) 66 (5) 3 (2) 6 (4)
 Hispanic 1822 (5) 288 (5) 252 (5) 48 (4) 10 (6) 3 (2)
 Other 1026 (3) 173 (3) 122 (3) 32 (2) 5 (3) 5 (4)
Education
 High school or less 6230 (16) 919 (16) 631 (14) 184 (14) 21 (13) 9 (6)
  Some college but no 
degree 7687 (19) 1299 (22) 941 (20) 221 (16) 32 (19) 27 (19)
  Associate or technical 
degree 5605 (14) 841 (14) 731 (16) 209 (15) 27 (16) 15 (11)
 Bachelor degree 10943 (27) 1438 (25) 1242 (27) 425 (31) 42 (25) 56 (40)
  Master or doctoral 
degree 9689 (24) 1310 (23) 1106 (24) 314 (23) 46 (27) 33 (24)
Age at menarche
 < 12 y 8025 (20) 1334 (23) 1037 (22) 214 (16) 33 (20) 28 (20)
 12-< 14 y 22654 (56) 3149 (54) 2565 (55) 786 (58) 86 (51) 82 (59)
 > = 14 y 9475 (24) 1324 (23) 1049 (23) 353 (26) 49 (29) 30 (21)
Parity
 0 child 7372 (18) 1011 (17) 769 (17) 295 (22) 30 (18) 33 (24)
 1 child 5763 (14) 850 (15) 702 (15) 209 (15) 29 (17) 21 (15)
 2 children 14683 (37) 2130 (37) 1778 (38) 496 (37) 63 (38) 53 (38)
 > = 3 children 12307 (31) 1813 (31) 1400 (30) 353 (26) 45 (27) 33 (24)
Age at first birth
  nonparous or no term 
pregnancy 8147 (21) 1140 (20) 864 (19) 317 (24) 34 (20) 40 (29)
 < 25 y 16625 (42) 2758 (48) 2011 (44) 384 (29) 51 (31) 33 (24)
 25-< 30 y 8953 (23) 1182 (21) 1052 (23) 363 (27) 50 (30) 43 (31)
 30-< 35 y 4201 (11) 479 (8) 489 (11) 201 (15) 22 (13) 12 (9)
 > = 35 y 1706 (4) 176 (3) 186 (4) 81 (6) 9 (5) 12 (9)
BMI at age 30
 < 18.5% kg/m2 1018 (3) 157 (3) 145 (3) 48 (4) 2 (1) 3 (2)
 18.5–24.9 kg/m2 30242 (76) 4294 (74) 3464 (75) 946 (70) 113 (68) 91 (65)
 25.0–29.9 kg/m2 6186 (16) 896 (16) 711 (15) 240 (18) 33 (20) 37 (26)
 > = 30.0 kg/m2 2376 (6) 425 (7) 294 (6) 116 (9) 19 (11) 9 (6)
Use of hormonal birth control
 Nonuser 6190 (16) 760 (13) 505 (11) 137 (10) 20 (12) 7 (5)
 < 10 y 22892 (57) 3538 (61) 2893 (62) 731 (54) 92 (55) 80 (57)
 > = 10 y 10841 (27) 1485 (26) 1234 (27) 482 (36) 56 (33) 53 (38)
Use of hormonal replacement therapy
 Never 23444 (58) 2866 (50) 2778 (60) 1231 (91) 134 (80) 127 (92)
 Estrogen only 7579 (19) 1596 (28) 856 (18) 78 (6) 27 (16) 7 (5)
Continued
www.nature.com/scientificreports/
5Scientific RepoRts | 5:14943 | DOi: 10.1038/srep14943
1.25)). However, women with nonmenstrually-related migraine had some evidence for increased risk 
(combined-analysis adjusted HR = 1.3 (0.93, 1.81)) while women with menstrually-related migraine had 
decreased risk (combined-analysis adjusted HR = 0.63 (0.42, 0.96)). The difference was statistically signif-
icant (P = 0.005) and the same contrasting effect directions were seen in both of the two studies. Again 
the meta-analysis results were similar to the combined-analysis results (adjusted HR = 1.3 (0.93, 1.82) 
and 0.61 (0.40, 0.94) for menstrually-related and nonmenstrually-related migraine, respectively). Similar 
associations were observed for the subcategory of invasive ER− /PR− /HER2− cancer (Table 2). We did 
not observe effect measure modification by age at risk (≥ 45 years or < 45), menopause status or by 
body mass index based on recalled average nonpregnant weight during their 30 s (data not shown). In a 
sensitivity analysis, we also fit a model adjusting for the known risk factors for breast cancer: race, age at 
menarche, age at first term birth, parity, menopause status, BMI in the 30 s, birth control use, hormone 
replacement therapy use, alcohol and smoking. Results were similar to those based on only adjusting for 
potential confounders identified by consideration of directed acyclic graphs (DAGs).
In a case-only analysis of invasive breast cancer modeling the odds of ER negative cancer, condi-
tional on cancer having occurred, nonmenstrually-related migraine was positively associated with 
estrogen-receptor negative (ER−) cancer whereas menstrually-related migraine was negatively associ-
ated with estrogen-receptor negative (ER−) cancer (combined-analysis test of heterogeneity P = 0.06) 
(Table  3). In a model for the odds of ER− /PR− cancer, conditional on cancer having occurred, cases 
with nonmenstrually-related migraine were more likely to have ER− /PR− cancer (combined-analysis 
OR = 1.26 (0.99, 1.60)) while cases with menstrually-related migraine were less likely to have ER− /PR− 
cancer (combined-analysis OR = 0.78 (0.59, 1.03), combined-analysis test of heterogeneity P = 0.044). 
The risk for other subcategories or DCIS versus non-DCIS did not differ appreciably by migraine type.
In a sensitivity analysis, we only categorized women as having migraine if they reported both a pos-
itive migraine history and a history of use of migraine medication. Similar, but slightly stronger, asso-
ciations for DCIS and ER− /PR− cancers were observed with this stricter migraine definition (data not 
shown). We reanalyzed our data focusing on histological subtypes and did not find any association in 
either ductal or lobular invasive breast cancer. (Data not shown.).
Discussion
We analyzed a sister-matched case-control study and a cohort study and neither showed an overall asso-
ciation between self-reported migraine headache and breast cancer. There was evidence for an inverse 
association between migraine and DCIS in the cohort study, and in the combined analysis, but limited 
evidence for that association in the Two Sister Study. However, the Two Sister Study included few cases 
with DCIS, and there was considerable overlap in the confidence intervals, indicating no important 
inconsistency between the two studies.
We considered whether medical screening bias could be a factor, since the Sister Study cohort par-
ticipants all have a first-degree family history of breast cancer, while the majority of cases in the retro-
spective Two Sister Study did not have a first-degree family history. Women with a sister with breast 
cancer who themselves have migraine may be more likely, because of their own chronic condition, to 
have regular medical care and hence also to be screened for breast cancer. However, instead of an inverse 
association, one would expect to see a positive association between migraine and DCIS if there were 
screening bias in the Sister Study, whereas the association we saw was negative.
Characteristic




















  Combined estrogen and 
progestin 9109 (23) 1326 (23) 1017 (22) 44 (3) 7 (4) 4 (3)
Migraine medication
 No N/A 1289 (22) 555 (12) N/A 48 (29) 13 (9)
 Yes N/A 4506 (78) 4090 (88) N/A 120 (71) 127 (91)
Menopause
 Premenopausal 12239 (30) 1354 (23) 1706 (37) 1163 (86) 110 (65) 116 (83)
 Postmenopausal 26612 (66) 4132 (71) 2733 (59) 93 (7) 35 (21) 10 (7)
  Premenopausal 
hysterectomy, with 
retained ovarian tissue
1303 (3) 321 (6) 212 (5) 95 (7) 23 (14) 14 (10)
Table 1.  Selected characteristics by migraine status and study. *All age-dependent variables, e.g., 
menopausal status, were values at enrollment for Sister Study and values at the sistership-defined index age 
for Two Sister Study. The numbers for each variable do not add up to the total due to missingness.
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Migraine, like breast cancer, is an estrogen-sensitive disorder that primarily affects women25. The sen-
sitivity of ER+ breast tumors to estrogen has enabled the development of effective therapeutic regimens, 
but hormone-receptor negative tumors remain a clinical challenge.
When we subcategorized migraine as menstrually-related versus nonmenstrually-related, and con-
sidered hormone-receptor-negative breast cancer, patterns emerged that were similar in the two studies. 
We saw increased estimated risk for hormone-insensitive ER− /PR− breast cancer in women reporting 
nonmenstrually-related migraine and decreased risk in women reporting menstrually-related migraine. 
Thus data from both studies are consistent with the possibility that women with hormone-insensitive 
migraine are at relatively increased risk for the more aggressive hormone-receptor-negative breast cancer.
The existing literature on migraine and breast cancer is mixed. Three case-control17,18,26 and three pro-
spective cohort studies16,19,27 previously examined the association between migraine and breast cancer. 
Four of them16–18,26 reported a negative association while two found none19,27. Mathes et al.18, Li et al. 
(2010)16 and Lowry et al.26 studied postmenopausal women only, while Li et al. (2009)17 and Winter et 
al. (2013)19 studied both premenopausal and postmenopausal women and found no difference between 
them in the association between migraine history and risk. Lowry et al.26 used a subset of the subjects in 
Mathes et al.18 and obtained more detailed information on migraine history for a more refined analysis. 
They observed that women with early onset migraine or long-duration migraine history had a reduced 
risk of ER+ breast cancer. In addition to invasive breast cancer, Li et al. (2010)16 also studied in situ 
breast cancer and found an inverse association with migraine, which was not statistically significant but 
is consistent with our finding. However, Winter et al.19,27 found no association with DCIS. Winter et al. 
(2015)27 performed a meta-analysis based on these six previous studies and provided a nice summary of 
the studies in their Supplementary Table 2.
Previous studies that did not categorize migraine by hormone sensitivity showed diverse results 
regarding the association between migraine and ER− /PR− breast cancer risk. An inverse association 
was reported by Mathes et al. (OR = 0.87 (0.56–1.36))18 and Li et al. (2009) (OR = 0.83 (0.70–0.99))17 
while a positive association was reported by Li et al. (2010) (OR = 1.16 (0.86, 1.57))16 and Winter et al. 
(OR = 1.28 (0.96, 1.71))19. In the Nurses’ Health Study II, the OR for ER− /PR− breast cancer was close 
to one (OR = 0.93 (0.73, 1.17)27. Previous studies also investigated the association by histologic subtype 
and reported similar effects for ductal and lobular carcinoma.
Cancer Type Study











Any Sister 1701 246 169 0.98 (0.88,1.09) 1.03 (0.90,1.18) 0.91 (0.77,1.07)
Two Sister 1157 139 122 0.97 (0.79,1.19) 0.97 (0.75,1.26) 0.97 (0.74,1.27)
Combined 2858 382 291 0.98 (0.89,1.07) 1.02 (0.91,1.15) 0.92 (0.80,1.06)
Invasive Sister 1220 189 124 1.03 (0.90,1.16) 1.10 (0.94,1.28) 0.94 (0.78,1.13)
Two Sister 976 121 103 0.97 (0.78,1.21) 1.00 (0.75,1.32) 0.94 (0.70,1.27)
Combined 2196 310 237 1.01 (0.90,1.13) 1.07 (0.93,1.22) 0.94 (0.80,1.10)
DCIS Sister 412 41 34 0.73 (0.57,0.94) 0.73 (0.53,1.01) 0.73 (0.51,1.05)
Two Sister 167 18 18 1.04 (0.61,1.79) 1.07 (0.51,2.24) 1.02 (0.49,2.11)
Combined 479 59 52 0.77 (0.62,0.96) 0.75 (0.56,1.01) 0.79 (0.58,1.08)
ER+ /PR+ invasive Sister 730 110 80 1.05 (0.89,1.23) 1.08 (0.88,1.32) 1.01 (0.80,1.28)
Two Sister 671 78 74 1.05 (0.79,1.37) 0.96 (0.68,1.36) 1.16 (0.79,1.69)
Combined 1401 188 154 1.04 (0.9,1.19) 1.03 (0.86,1.23) 1.04 (0.86,1.27)
ER− /PR− invasive Sister 163 30 13 1.01 (0.72,1.42) 1.29 (0.87,1.91) 0.68 (0.39,1.20)#a
Two Sister 196 31 19 0.83 (0.52,1.33) 1.34 (0.7,2.57) 0.54 (0.28,1.02)#b
Combined 359 61 32 0.96 (0.73,1.26) 1.30 (0.93,1.81) 0.63 (0.42,0.96)#c
ER− /PR− /HER2− invasive Sister 111 20 9 1.05 (0.7,1.58) 1.34 (0.84,2.14) 0.70 (0.35,1.39)
Two Sister 130 18 11 0.79 (0.43,1.45) 1.37 (0.58,3.24) 0.50 (0.22,1.12)
Combined 209 38 18 0.98 (0.70,1.37) 1.33 (0.89,1.99) 0.64 (0.38,1.07)#d
Table 2.  Multivariable adjusted hazard ratios for breast cancer. #a–#d We tested for heterogeneity between 
menstrual and nonmenstrual migraine and observed P ≤ 0.05 for a–d: #aP = 0.05; #bP = 0.04; #cP = 0.005; 
#dP = 0.02. *Hazard ratios for breast cancer with nonmigraine as the reference group from Cox regression 
adjusting for race, age at menarche, BMI at age 30, age at first birth and menopause status. Study was 
adjusted for in the combined analysis through stratification.
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In our analysis, an association of migraine with breast cancer was not seen in general. However, with 
further exploration a relationship with ER− /PR− cancer was seen when we categorized migraine by 
hormone sensitivity. This observation, based on subcategories, would require replication. Among the 
six previous publications, only Lowry et al.26, in carrying out a subset analysis of the subjects in Mathes 
et al.18, obtained more detailed information on migraine history distinguishing menstrually-related 
from nonmenstrually-related migraine. However, they did not specifically study ER− /PR− cancer but 
reported results for ER− cancer. Their case sample size was small for ER- cancer but their reported 
contrast in ORs was consistent with our findings (OR = 1.8 for nonmenstrually-related migraine and 
OR = 0.5 for menstrually-related migraine).
Some limitations of our study are worth mentioning. Information on migraine history was self-reported 
and some misclassification may exist. Nevertheless, a re-analysis of the data by categorizing women as 
having migraine only if they also reported use of migraine medication produced similar results to those 
based on the original self-reported migraine status.
We also have used self-reported information on whether their migraine attacks tended to be timed 
with the menstrual cycle, as “menstrually-related migraine,” rather than the stricter category of “menstrual 
migraine” defined by the International Headache Society28. It would have been interesting to see whether 
a stricter classification might have strengthened the apparent risk contrast that we found. We also were 
unable to distinguish between women with only menstrual migraine and women with both types, nor 
did we have access to medical records related to migraine. However, medical records would likely also 
need to rely on the woman’s self-report. The frequency of reporting menstrually-related migraine fell off 
after menopause in our study, suggesting that some postmenopausal participants may have mistakenly 
assumed we were asking about their current pattern. Consistent with that possible explanation is the 
observation that when we exclude Sister Study women who had completed the questionnaire more than 
twelve years after their menopause, the results for ER− /PR− invasive cancer become somewhat stronger 
than those shown in Table 2: HR = 0.58; CI = (0.3, 1.15) for menstrually-related migraine and HR = 1.55; 
















Invasive ER+ versus 
ER− 
Sister ER+ 934 131 97 1 1
ER− 181 31 16 1.14 (1.75,0.74) 0.77 (1.35,0.44)
Two Sister ER+ 754 86 83 1 2
ER− 214 34 19 1.33 (2.08,0.86) 0.84 (1.43,0.49)
Combined ER+ 1688 217 180 1 3
ER− 395 65 35 1.23 (1.67,0.9) 0.79 (1.16,0.54)
Invasive**
ER/PR status
Sister ER+ /PR+ 730 110 80 1 1
ER+ /PR− 157 20 13 0.94 (0.63,1.41) 0.91 (0.59,1.42)
ER− /PR− 163 31 13 1.27 (0.90,1.80) 0.71 (0.46,1.09)
Two Sister ER+ /PR+ 671 77 75 1 1
ER+ /PR− 72 7 7 0.90 (0.50,1.62) 1.02 (0.56,1.84)
ER− /PR− 196 31 19 1.26 (0.90,1.76) 0.85 (0.59,1.24)
Combined# ER+ /PR+ 1401 187 155 1 1
ER+ /PR− 229 27 20 0.92 (0.66,1.27) 0.94 (0.67,1.33)
ER− /PR− 359 62 32 1.26 (0.99,1.60) 0.78 (0.59,1.03)
DCIS versus Invasive
Sister DCIS 1220 189 124 1 1
Invasive 445 51 44 1.33 (0.96,1.86) 1.08 (0.75,1.57)
Two Sister DCIS 976 121 103 1 1
Invasive 170 18 18 1.19 (0.70,2.02) 1.06 (0.62,1.80)
Combined DCIS 2196 310 227 1 1
Invasive 615 69 62 1.28 (0.96,1.69) 1.05 (0.78,1.42)
Table 3.  Case only analysis for heterogeneity in risk for different breast cancer subcategories. *Odds 
ratios from logistic regression adjusting for race, age at menarche, age at first birth, menopause status, BMI 
at age 30 and age at breast cancer diagnosis. **There were few in the ER− /PR+ category and those events 
were treated as censoring times in the Sister Study and affected families were eliminated in the Two Sister 
Study analysis. &In the merged data analysis a dummy variable for study was also adjusted in the model. #We 
tested for heterogeneity between menstrual and nonmenstrual migraine and observed P = 0.044.
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Finally, for the Sister Study we used information collected at baseline, without updating it during 
follow-up. However, considering that 93% of migraine cases are diagnosed before age 50 2 and our 
follow-up time is limited (averaging 5.34 years) few women would have developed migraine during 
follow up. A sensitivity analysis that limited follow-up to the first 3 years after enrollment produced very 
similar results.
Our study has several strengths. One is that the findings with respect to ER− /PR− breast cancer were 
reproduced in two studies with very different designs (Table  2): a large prospective cohort of women 
with a first-degree family history of breast cancer and a retrospective family-based case-control study of 
people, most of whom did not have a family history. The same information on confounders was avail-
able in both studies and the two studies provided statistically independent and similar findings relating 
migraine to ER− /PR− breast cancer.
In summary, using data from a prospective cohort study and a sister-controlled retrospective study of 
breast cancer we found evidence that migraine is negatively associated with DCIS. However, the DCIS 
association was based on the Sister Study cohort and was not observed in the Two Sister Study.
When attention was turned instead to invasive ER− /PR− breast cancer, we identified statistically 
significant heterogeneity in risk in women with nonmenstrually-related versus menstrually-related 
migraine, with the same pattern evident in both studies. This observation, while needing future con-
firmation, suggests that women with hormone-insensitive migraine who develop breast cancer may be 
more likely to produce a hormone-insensitive ER− /PR− tumor. The inverse observation that a history 
of menstrually-related migraine appears to be protective against ER− /PR− breast cancer has now been 
noted twice (our combined and that of Lowry et al.26).
These could be chance findings and one should generally be wary of inferences based on subcategories 
of the predictor and sub-categorizations of the outcome. The underlying biology that would explain the 
observed disparate relationships is not clear. To speculate, we think it is unlikely that hormone-sensitive 
tumors are caused by hormone-sensitive migraine and prevented by hormone-insensitive migraine. A 
more parsimonious explanation would be that some women, perhaps based on genetic predisposition, 
tend to express hormone receptors and they tend to do so both in connection with migraine and as part 
of the phenotype when they develop a breast tumor. Our findings will need to be replicated in future 
studies, but such a phenotype-modifying mechanism would be consistent with the absence of an overall 
effect of migraine on risk of breast cancer.
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